Positive CHMP opinion for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension readopted

ALLSCHWIL, SWITZERLAND – 01 April 2016 – Actelion (SIX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), readopted its positive opinion for the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), for the treatment of pulmonary arterial hypertension.

The procedural re-adoption of the opinion was the result of clarifications requested by the European Commission. The European Commission decision is now expected in the coming months.

More details: http://www.genevaromfarm.ro/actelion-receives-positive-chmp-opinion-for-uptravi-selexipag-for-the-long-term-treatment-of-pulmonary-arterial-hypertension/

Source: https://www.actelion.com/en/our-company/news-and-events.page?newsId=1999741